

DEC 13 2001

**510(k) Summary**

K013739  
page 1 of 2

This 510(k) summary for the EBI® XFIX® DFS® System is provided as required per Section 513(I)(3) of the Food, Drug and Cosmetic Act.

**1. Sponsor:**

EBI, L.P.  
100 Interpace Parkway  
Parsippany, NJ 07054

**Contact Person:** Frederic Testa

**Telephone:** (973) 299-9300, ext.2208

**Date Prepared:** November 12, 2001

**2. Proprietary Name:** EBI® XFIX® DFS® System

**Common Name:** External Fixation Device

**Classification Name:** Single Multiple Component Metallic Bone Fixation Appliances and Accessories, 21 CFR 888.3030.

**3. Predicate or Legally Marketed Devices:**

- EBI® XFIX® DFS® System (K953406)

**4. Description of Device:**

The system consists of fixation components and implantable bone screws. The **EBI® XFIX® DFS® System** is utilized in the following manner: bone screws are inserted through the patient's skin and soft tissue, and into the bone. The fixator frame of the **EBI® XFIX® DFS® System** is attached to the shanks of the bone screws. This submission is for the availability of a **Central Body Variable Clamp**.

**5. Intended Use:**

The **EBI® XFIX® DFS® System** is a unilateral external fixation device intended for use in the treatment of bone conditions including leg lengthening, corrective osteotomies, arthrodesis, fracture fixation, and other bone conditions amenable to treatment by use of the external fixation modality.

**6. Materials:**

The components of the System may be manufactured from materials such as titanium alloy, stainless steel, aluminum, and carbon fiber.

**7. Comparison of the technological characteristics of the device to predicate devices:**

- The modified EBI XFIX DFS System is fabricated from the same materials as the components of the currently marketed EBI XFIX DFS System.
- The modified EBI XFIX DFS System and the currently marketed EBI XFIX DFS System are both indicated for the treatment of bone conditions, including leg lengthening, osteotomies, arthrodesis, fracture fixation, and other bone conditions amenable to treatment by use of the external fixation modality
- The bone screw clamps of the modified EBI XFIX DFS System, like the bone screw clamps currently marketed in the EBI XFIX DFS System, are designed for attachment to the bone screws.
- The additional component of the EBI XFIX DFS System, like the components of the currently marketed EBI XFIX DFS System, is provided non-sterile.
- There are no significant differences between the proposed EBI<sup>®</sup> XFIX<sup>®</sup> DFS<sup>®</sup> System and the currently marketed EBI<sup>®</sup> XFIX<sup>®</sup> DFS<sup>®</sup> System. It is substantially equivalent\* to the predicate device with regard to intended use, materials, and function.

\*Any statement made in conjunction with this submission regarding a determination of substantial equivalence to any other product is intended only to relate to whether the product can be lawfully marketed without pre-market approval or reclassification and is not intended to be interpreted as an admission or any other type of evidence in patent infringement litigation. [Establishment Registration and Premarket Notification Procedures, Final Regulation, Preamble, August 23, 1977, FR 42520 (Docket No. 76N-0355.)]



DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

Food and Drug Administration  
9200 Corporate Boulevard  
Rockville MD 20850

Mr. Frederick Testa  
Regulatory Affairs Specialist  
EBI, L.P.  
100 Interpace Parkway  
Parsippany, New Jersey 07054

DEC 13 2001

Re: K013739  
Trade/Device Name: EBI® XFIX® DFS® System  
Regulation Number: 888.3030  
Regulation Name: Single/multiple component metallic bone  
fixation appliances and accessories  
Regulatory Class: II  
Product Code: LXT  
Dated: November 12, 2001  
Received: November 13, 2001

Dear Mr. Testa:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.


If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and additionally 21 CFR Part 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at (301) 594-4659. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address <http://www.fda.gov/cdrh/dsma/dsmamain.html>

Sincerely yours,

A handwritten signature in black ink, appearing to read "for Mark N. Witten", is written over the typed name.

Celia M. Witten, Ph.D., M.D.

Director

Division of General, Restorative  
and Neurological Devices

Office of Device Evaluation

Center for Devices and  
Radiological Health

Enclosure

**STATEMENT OF INDICATIONS FOR USE**

---


Page 1 of 1

510(k) Number (if known): K013739

Device Name: EBI® XFIX® DFS® System

**Indications For Use:**

The EBI® XFIX® DFS® System is a unilateral external fixation device intended for use in the treatment of bone conditions including leg lengthening, osteotomies, arthrodesis, fracture fixation, and other bone conditions amenable to treatment by use of the external fixation modality.

  
(Division Sign-Off)  
Division of General, Restorative  
and Neurological Devices  
510(k) Number K013739

(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE  
IF NEEDED)

\_\_\_\_\_  
Concurrence of CDRH, Office of Device Evaluation (ODE)

Prescription Use X  
(Per 21 CFR 801.109)

OR

Over-The-Counter Use

(Optional Format 1-2-96)